Efficacy and tolerability of adjunctive perampanel treatment in children under 12 years of age with refractory epilepsy |
Yun, Yuni
(Department of Pediatrics, School of Medicine, Kyungpook National University)
Kim, Dongsub (Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine) Lee, Yun-Jeong (Department of Pediatrics, School of Medicine, Kyungpook National University) Kwon, Soonhak (Department of Pediatrics, School of Medicine, Kyungpook National University) Hwang, Su-Kyeong (Department of Pediatrics, School of Medicine, Kyungpook National University) |
1 | Brodie MJ. Antiepileptic drug therapy the story so far. Seizure 2010;19:650-5. DOI |
2 | Loscher W, Schmidt D. Modern antiepileptic drug development has failed to deliver: ways out of the current dilemma. Epilepsia 2011;52:657-78. DOI |
3 | Rudzinski LA, Velez-Ruiz NJ, Gedzelman ER, Mauricio EA, Shih JJ, Karakis I. New antiepileptic drugs: focus on ezogabine, clobazam, and perampanel. J Investig Med 2016;64:1087-101. DOI |
4 | Plosker GL. Perampanel: as adjunctive therapy in patients with partial-onset seizures. CNS Drugs 2012;26:1085-96. DOI |
5 | Shih JJ, Tatum WO, Rudzinski LA. New drug classes for the treatment of partial onset epilepsy: focus on perampanel. Ther Clin Risk Manag 2013;9:285-93. DOI |
6 | Gidal BE, Laurenza A, Hussein Z, Yang H, Fain R, Edelstein J, et al. Perampanel efficacy and tolerability with enzyme-inducing AEDs in patients with epilepsy. Neurology 2015;84:1972-80. DOI |
7 | De Liso P, Moavero R, Coppola G, Curatolo P, Cusmai R, De Sarro G, et al. Current role of perampanel in pediatric epilepsy. Ital J Pediatr 2017;43:51. DOI |
8 | Swiderska N, Tan HJ, Rajai A, Silwal A, Desurkar A, Martland T. Effectiveness and tolerability of Perampanel in children, adolescents and young adults with refractory epilepsy: a UK national multicentre study. Seizure 2017;52:63-70. DOI |
9 | Falco-Walter JJ, Scheffer IE, Fisher RS. The new definition and classification of seizures and epilepsy. Epilepsy Res 2018;139:73-9. DOI |
10 | Biro A, Stephani U, Tarallo T, Bast T, Schlachter K, Fleger M, et al. Effectiveness and tolerability of perampanel in children and adolescents with refractory epilepsies: first experiences. Neuropediatrics 2015;46:110-6. DOI |
11 | Wirrell E, Wong-Kisiel L, Mandrekar J, Nickels K. Predictors and course of medically intractable epilepsy in young children presenting before 36 months of age: a retrospective, population-based study. Epilepsia 2012;53:1563-9. DOI |
12 | De Liso P, Vigevano F, Specchio N, De Palma L, Bonanni P, Osanni E, et al. Effectiveness and tolerability of perampanel in children and adolescents with refractory epilepsies-An Italian observational multicenter study. Epilepsy Res 2016;127:93-100. DOI |
13 | Heyman E, Lahat E, Levin N, Epstein O, Lazinger M, Berkovitch M, et al. Tolerability and efficacy of perampanel in children with refractory epilepsy. Dev Med Child Neurol 2017;59:441-4. DOI |
14 | Gidal BE, Ferry J, Majid O, Hussein Z. Concentration-effect relationships with perampanel in patients with pharmacoresistant partialonset seizures. Epilepsia 2013;54:1490-7. DOI |
15 | Kwan P, Brodie MJ, Laurenza A, FitzGibbon H, Gidal BE. Analysis of pooled phase III trials of adjunctive perampanel for epilepsy: impact of mechanism of action and pharmacokinetics on clinical outcomes. Epilepsy Res 2015;117:117-24. DOI |